Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026.

Fiscal 2027 margin guidance includes an expected 100-basis-point drag from the Elegen agreements and SynPlexity acquisition.

Rhea-AI Summary

Azenta (AZTA) reported fiscal 2026 revenue of $622 million, with annual growth accompanied by a loss from continuing operations. Revenue rose 5%, or 2% organically, while continuing-operations diluted EPS fell to ($3.50) from $0.53. A $149 million non-cash goodwill impairment contributed to the annual operating loss. Fourth-quarter revenue rose 5% to $167 million; continuing-operations diluted EPS fell to $0.14 from $1.12.

Azenta expects fiscal 2027 revenue of approximately $648–$660 million, organic growth of approximately 3%–5%, and adjusted EBITDA margin expansion of 200–250 basis points. On October 28, it acquired SynPlexity for a $15 million base cash price and signed Elegen technology agreements. Expected Elegen capital deployment is approximately $32–$71 million. Cash, cash equivalents, restricted cash and marketable securities totaled $506 million at September 30, 2026.

Positive

• Fiscal 2026 revenue rose 5% to $622 million, with organic growth of 2%.
• Fourth-quarter revenue rose 5% to $167 million, with organic growth of 2%.
• Sample Management Solutions annual revenue rose 6% to $344 million; organic revenue increased 2%.
• Sample Management Solutions quarterly revenue rose 9% to $94 million; organic revenue increased 4%.
• Multiomics annual revenue rose 3% to $277 million; organic revenue increased 1%.
• Fourth-quarter gross margin increased 60 basis points to 46.0% year over year.
• Fourth-quarter operating margin increased 30 basis points to 1.5%, with operating income of $2.5 million.
• Fourth-quarter adjusted diluted EPS from continuing operations increased 33% to $0.28.
• Fiscal 2026 operating cash flow was $58 million, with free cash flow of $27 million.
• Fourth-quarter operating cash flow was $22 million, with free cash flow of $12 million.
• B Medical Systems sale completed July 1, 2026; the $35 million vendor loan plus interest was repaid September 3.
• Elegen agreements provide an exclusive, royalty-free license to certain gene synthesis and cell-free cloning technologies.
• SynPlexity acquisition completed for a $15.0 million base cash price, intended to expand Multiomics gene synthesis capabilities.
• Fiscal 2027 revenue is expected at approximately $648–$660 million, with approximately 3%–5% organic growth.
• Fiscal 2027 segment organic growth is expected at mid-single-digits for Sample Management Solutions and low-single-digits for Multiomics.
• Fiscal 2027 adjusted EBITDA margin is expected to expand 200–250 basis points, including the expected acquisition-related dilution.
• Fiscal 2027 free cash flow is expected to improve approximately 25% relative to fiscal 2026.
• First-quarter fiscal 2027 organic revenue growth is expected at approximately 3%–4% year over year.
• First-quarter fiscal 2027 adjusted EBITDA margin is expected to expand approximately 100–150 basis points year over year.
• Fiscal 2026 repurchases totaled 4.4 million shares for $118.2 million, excluding fees, commissions and excise tax.

Negative

• Fiscal 2026 continuing-operations net loss was $158 million, versus $24 million net income; diluted EPS fell to ($3.50).
• Fiscal 2026 total diluted loss per share widened to ($3.70) from ($1.22).
• Fiscal 2026 operating loss reached $174.7 million; operating margin fell to (28.1%) from (4.5%).
• Fiscal 2026 non-cash goodwill impairment totaled $149 million.
• Fiscal 2026 gross margin declined 130 basis points to 44.2%.
• Automated Stores quality remediation and rework, lower-volume cost absorption and increased inventory reserves pressured annual gross margin.
• Fourth-quarter continuing-operations net income fell 89% to $6 million; diluted EPS declined 88% to $0.14.
• Fourth-quarter total diluted EPS fell 86% to $0.16.
• Fourth-quarter operating expenses increased 6% to $74 million.
• Fourth-quarter Multiomics revenue was flat at $73 million, while organic revenue declined 1%.
• Fourth-quarter adjusted EBITDA declined 7% to $19 million; margin fell to 11.6% from 13.0%.
• Fiscal 2026 adjusted EBITDA declined 12% to $58 million; margin fell to 9.4% from 11.2%.
• Fiscal 2026 adjusted diluted EPS from continuing operations declined 6% to $0.48.
• Fiscal 2026 adjusted operating margin declined 110 basis points to 1.6%.
• Elegen's initial five-year license requires $23.0 million in fixed payments and carries specified restrictions.
• Elegen aggregate capital deployment is expected at approximately $32.0–$71.0 million, depending on equipment purchases and license conversion.
• SynPlexity contingent consideration totals up to $10.0 million, tied to a revenue milestone through September 30, 2029.
• Elegen and SynPlexity are expected to dilute fiscal 2027 adjusted EBITDA margin by 100 basis points.
• Fiscal 2027 revenue outlook's high end includes potential Elegen and SynPlexity contributions during integration, scale-up and commercialization.

News Explained

By September 30, 2026, Azenta had repurchased 4.4 million shares for $118.2 million; $131.8 million remained available under its $250 million repurchase authorization, which runs through December 31, 2028, so that remainder is capacity, not a reported additional purchase.

Key Figures

FY26 continuing revenue: $622 million FY26 total diluted EPS: ($3.70) FY26 adjusted EBITDA: $58.3 million +5 more

FY26 continuing revenue

$622 million

Fiscal 2026; up 5% year over year

FY26 total diluted EPS

($3.70)

Fiscal 2026

FY26 adjusted EBITDA

$58.3 million

Continuing operations; down 12% year over year

Cash and liquidity

$506 million

Cash, cash equivalents, restricted cash and marketable securities at September 30, 2026

FY27 revenue guidance

$648–$660 million

Reported revenue from continuing operations

FY27 organic revenue growth guidance

3%–5%

Expected year-over-year growth

FY27 adjusted EBITDA margin expansion

200–250 basis points

Year over year; includes expected 100-basis-point dilution associated with Elegen and SynPlexity

FY27 free cash flow outlook

Improve 25%

Relative to fiscal 2026

Historical Context

2 past events · Latest: Oct 30

2 events

1. Oct 30

   Strategic investment

   24h Move

   -5.3%

   Announced Elegen licensing agreement and completed SynPlexity acquisition to expand gene-synthesis capabilities.

2. Aug 04

   Earnings report

   24h Move

   +5.6%

   Reported Q3 revenue growth and positive organic growth alongside adjusted EBITDA and diluted EPS results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

free cash flow, adjusted ebitda, goodwill impairment, accelerated share repurchase agreement

4 terms

free cash flow financial

"free cash flow (cash flow from operations less capital expenditures) was $27 million"

Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.

View in glossary

adjusted ebitda financial

"Adjusted EBITDA was $58.3 million, and Adjusted EBITDA margin was 9.4%"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

goodwill impairment financial

"a non-cash goodwill impairment charge of $149 million"

Goodwill impairment occurs when a company’s valued reputation or brand strength, known as goodwill, is found to be worth less than previously recorded on its financial statements. This usually happens when the company's performance declines or market conditions change, signaling that the expected benefits from acquisitions or brand value are no longer as strong. It matters to investors because it can indicate that a company's assets are less valuable than initially thought, potentially affecting its overall financial health.

accelerated share repurchase agreement financial

"including under an accelerated share repurchase agreement"

An accelerated share repurchase agreement is a deal where a company quickly buys back its own shares by paying a financial institution up front, while the institution delivers shares it borrows and settles the exact quantity later based on market prices. For investors this matters because it immediately reduces the number of shares outstanding and can boost per-share earnings, change cash and leverage levels, and signal management’s view on the stock’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Q4'26 reported revenue growth of 5% year over year and 2% on an organic basis
• FY'26 reported revenue growth of 5% year over year and 2% on an organic basis
• FY'27 reported revenue expected to range from $648 to $660 million
• FY'27 organic revenue growth expected to range between 3% to 5% year over year
• FY'27 adjusted EBITDA margin expected to expand approximately 200 to 250 basis points year over year

BURLINGTON, Mass., Nov. 10, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2026.

B Medical Systems is reported as discontinued operations, with its historical results reflected in total diluted EPS. The Company completed the sale of the business on July 1, 2026, and received full repayment of the $35 million vendor loan, together with accrued interest, on September 3, 2026.
		Quarter Ended						Year Ended
Dollars in millions, except per share data		September 30,		September 30,				September 30,		September 30,
		2026		2025		Change		2026		2025		Change
Revenue from Continuing Operations		$       167		$       159		5 %		$       622		$       594		5 %
Organic growth						2 %						2 %
Sample Management Solutions		$         94		$         86		9 %		$       344		$       325		6 %
Multiomics		$         73		$         73		0 %		$       277		$       269		3 %
Diluted EPS Continuing Operations		$       0.14		$       1.12		(88) %		$     (3.50)		$      0.53		NM
Diluted EPS Total		$       0.16		$       1.11		(86) %		$     (3.70)		$     (1.22)		NM
Net Income (Loss) - Continuing Operations		$            6		$          52		(89) %		$      (158)		$         24		NM
Adjusted Diluted EPS Continuing Operations		$       0.28		$       0.21		33 %		$       0.48		$       0.51		(6) %
Adjusted EBITDA - Continuing Operations		$          19		$          21		(7) %		$          58		$          66		(12) %
Adjusted EBITDA Margin - Continuing Operations		11.6 %		13.0 %				9.4 %		11.2 %

Management Comments
"We closed fiscal 2026 with improving momentum, delivering stronger performance in the second half of the year. Our businesses have strong market positions and differentiated capabilities, and we are seeing progress from our efforts to improve commercial execution and operating efficiency," said Dr. Martin Madaus, Interim President and Chief Executive Officer. "We also took several actions to streamline our cost structure while advancing the strategic objective to turn Multiomics into a growth engine for Azenta."

Dr. Madaus continued, "Fiscal 2027 is about consistent execution and accelerating performance. We are focused on driving organic growth, expanding profitability and cash generation, and executing on our strategic initiatives."

Fourth Quarter Fiscal 2026 Results - Continuing Operations

• Revenue was $167  million, up 5% year over year. Organic revenue, which excludes a nominal impact from foreign exchange and a 3-percentage point impact from the acquisition of UK Biocentre Limited, was up 2% year over year, reflecting organic growth in Sample Management Solutions, partially offset by an organic revenue decline in Multiomics.
• Sample Management Solutions revenue was $94 million, up 9% year over year.
  • Organic revenue, which excludes the impact from foreign exchange and the contribution from the acquisition of UK Biocentre Limited, was up 4%, mainly driven by higher revenue in Sample Repository Services and Consumables and Instruments, partially offset by lower revenue in Automated Stores.
• Multiomics revenue was $73 million, flat year over year.
  • Organic revenue, which excludes the impact from foreign exchange, was down 1% year over year, primarily driven by lower Sanger Sequencing and Next Generation Sequencing revenue, partially offset by growth in Gene Synthesis.

Summary of GAAP Earnings Results - Continuing Operations

• Operating income was $2.5 million. Operating margin was 1.5%, an increase of 30 basis points year over year.
  • Gross margin was 46.0%, an increase of 60 basis points year over year, primarily driven by improved operating leverage, favorable mix and the benefits of ongoing cost initiatives. This improvement was partially offset by unfavorable fixed-cost absorption associated with lower sales volumes in certain areas of the portfolio, as well as quality remediation and rework activities in Automated Stores.
  • Operating expenses in the quarter were $74 million, up 6% year over year, primarily driven by higher research and development expenses, higher selling, general and administrative expenses, as well as higher restructuring charges, partially offset by a reversal of stock-based compensation expense related to our former Chief Executive Officer's unvested awards.
• Total other income included $5 million of net interest income, consistent with the prior year period.
• Diluted EPS from continuing operations was $0.14 compared to $1.12 in the fourth quarter of fiscal year 2025. Diluted EPS from discontinued operations was $0.02, compared to ($0.02) a year ago. Total diluted EPS was $0.16, compared to $1.11 a year ago.

Summary of Non-GAAP Earnings Results - Continuing Operations

• Adjusted operating income was $11.5  million. Adjusted operating margin was 6.9%, an increase of 120 basis points year over year.
  • Adjusted gross margin was 47.2%, an increase of  50  basis points year over year, primarily driven by improved operating leverage, favorable mix and the benefits of ongoing cost initiatives. This improvement was partially offset by unfavorable fixed-cost absorption associated with lower sales volumes in certain areas of the portfolio, as well as quality remediation and rework activities in Automated Stores.
  • Adjusted operating expenses in the quarter were $67 million, up 3% year over year, mainly driven by higher research and development expenses, partially offset by a reversal of stock-based compensation expense related to our former Chief Executive Officer's unvested awards.
• Adjusted EBITDA was $19.4 million, and Adjusted EBITDA margin was 11.6%, a decrease of 140 basis points year over year.
• Adjusted diluted EPS was $0.28, compared to $0.21 one year ago.

Full Year Fiscal 2026 Results - Continuing Operations

• Revenue was $622  million, up 5% year over year. Organic revenue, which excludes a 1-percentage point impact from foreign exchange and a 2-percentage point impact from the acquisition of UK Biocentre Limited, was up 2% year over year, reflecting higher revenue in Sample Management Solutions and Multiomics.
• Sample Management Solutions revenue was $344 million, up 6% year over year.
  • Organic revenue, which excludes the impact from foreign exchange and the contribution from the acquisition of UK Biocentre Limited, was up 2%, mainly driven by higher revenue in Sample Repository Services and Consumables and Instruments, partially offset by lower revenue in Automated Stores and Cryogenic Systems.
• Multiomics revenue was $277 million, up 3% year over year.
  • Organic revenue, which excludes the impact from foreign exchange, was up 1% year over year, primarily driven by higher revenue in Next Generation Sequencing and Gene Synthesis, partially offset by lower Sanger Sequencing revenue.

Summary of GAAP Earnings Results - Continuing Operations

• Operating loss was $174.7 million. Operating margin was (28.1%), compared to (4.5%) in fiscal 2025.
  • Gross margin was 44.2%, a decrease of 130 basis points year over year, primarily driven by unfavorable fixed-cost absorption associated with lower sales volumes in certain areas of the portfolio as well as costs related to quality remediation and rework activities in Automated Stores, and an increase in excess and obsolete inventory reserves. These impacts were partially offset by improved operating leverage and the benefits of ongoing cost initiatives.
  • Operating expenses were $450 million, an increase of 51% year over year, primarily driven by a non-cash goodwill impairment charge of $149 million. The increase also reflects higher research and development expenses, partially offset by lower selling, general and administrative expenses, including a reversal of stock-based compensation expense related to our former Chief Executive Officer's unvested awards.
• Total other income included $18 million of net interest income and $6 million of other income, including $4 million related to the non-cash settlement of a preexisting contractual relationship with UK Biocentre Limited, compared with $19 million and $1 million, respectively, in fiscal 2025.
• Diluted EPS from continuing operations was ($3.50) compared to $0.53 in fiscal year 2025. Diluted EPS from discontinued operations was ($0.20), compared to ($1.75) a year ago. Total diluted EPS was ($3.70), compared to ($1.22) a year ago.

Summary of Non-GAAP Earnings Results - Continuing Operations

• Adjusted operating income was $9.8 million. Adjusted operating margin was 1.6%, a decrease of 110 basis points year over year.
  • Adjusted gross margin was 45.5%, a decrease of 130 basis points year over year, primarily driven by unfavorable fixed-cost absorption associated with lower sales volumes in certain areas of the portfolio as well as costs related to quality remediation and rework activities in Automated Stores, and an increase in excess and obsolete inventory reserves. These impacts were partially offset by improved operating leverage and the benefits of ongoing cost initiatives.
  • Adjusted operating expenses were $273 million, an increase of 4% year over year, driven by higher research and development expenses and higher selling, general and administrative expenses, partially offset by the reversal of stock-based compensation expense related to our former Chief Executive Officer's unvested awards.
• Adjusted EBITDA was $58.3 million, and Adjusted EBITDA margin was 9.4%, a decrease of 180 basis points year over year.
• Adjusted diluted EPS was $0.48, compared to $0.51 one year ago.

Cash and Liquidity as of September 30, 2026

• The Company ended fiscal year 2026 with a total balance of cash, cash equivalents, restricted cash and marketable securities of $506 million.
• Operating cash flow was $22 million in the quarter. Capital expenditures were $10 million, and free cash flow (cash flow from operations less capital expenditures) was $12 million. For the full year, operating cash flow was $58 million, capital expenditures were $30 million, and free cash flow was $27 million.  

Recent Strategic Investments
Elegen Agreements

• On October 28, 2026, the Company entered into a Technology, Equipment and License Agreement and a Master Services and Supply Agreement with Elegen Corp. ("Elegen") to expand the Company's gene synthesis capabilities. Under the agreements, the Company obtained an exclusive, royalty-free license to certain Elegen gene synthesis and cell-free cloning technologies, subject to certain restrictions specified in the agreements, and entered into related equipment, supply and service arrangements. The license has an initial five-year term and requires fixed license payments totaling $23.0 million. The Company has an option, exercisable between 12 and 18 months after execution, to convert the license to an irrevocable, perpetual, exclusive, royalty-free license for $25.0 million, plus any unpaid license fees, subject to the license's terms. Aggregate capital deployment under the agreements is expected to range from approximately $32.0 million to $71.0 million, depending on future equipment purchases and whether the Company exercises the conversion option.

SynPlexity Acquisition

• On October 28, 2026, the Company acquired SynPlexity Inc. ("SynPlexity"), a synthetic biology company, for a base purchase price of $15.0 million in cash, of which approximately $2.5 million was held back, subject to customary closing and post-closing adjustments. The purchase agreement also provides for contingent consideration of up to $10.0 million based on the achievement of a specified revenue milestone through September 30, 2029. SynPlexity is a DNA assembly technology company providing products and services centered on large, multiplexed gene libraries for functional screening, drug discovery, therapeutics, and other applications. The acquisition is intended to expand the Company's gene synthesis capabilities within its Multiomics business. Due to the timing of the acquisition, the initial accounting for the business combination is incomplete and certain acquisition-related disclosures are not yet available.

Share Repurchase Program Update

• On December 8, 2025, our Board of Directors approved a share repurchase program authorizing the repurchase of up to $250 million of our common stock through December 31, 2028, or the 2025 Repurchase Program. Repurchases under the 2025 Repurchase Program may be made in the open market or through privately negotiated transactions (including under an accelerated share repurchase agreement), or by other means, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Exchange Act, subject to market and business conditions, legal requirements, and other factors. During the fiscal year ended September 30, 2026, the Company repurchased 4.4 million shares of common stock for $118.2 million (excluding fees, commissions, and excise tax) in open market repurchases pursuant to the 2025 Repurchase Program. As of September 30, 2026, $131.8 million remained available for future repurchases under the 2025 Repurchase Program.

First Quarter Fiscal 2027 Guidance

• Total organic revenue growth is expected to range approximately between 3%-4% relative to the first quarter of fiscal 2026.
• Adjusted EBITDA margin is expected to expand by approximately 100 to 150 basis points relative to the first quarter of fiscal 2026.

Full Year Fiscal 2027 Guidance

The Company expects total reported revenue from continuing operations to range approximately between $648 to $660 million for the fiscal year ending September 30, 2027.

• Total organic revenue growth is expected to range approximately between up 3% to 5% relative to fiscal 2026.
• Organic revenue for Sample Management Solutions is expected to grow mid-single-digits.
• Organic revenue for Multiomics is expected to grow low-single-digits.
• The high end of the fiscal 2027 revenue outlook includes the potential contributions from Elegen and SynPlexity. Fiscal 2027 is expected to be primarily a year of integration, scale-up, and commercialization of these capabilities.
• Adjusted EBITDA margin expansion of 200 to 250 basis points year-over-year, inclusive of the expected dilution of 100 basis points associated with the Elegen agreements and SynPlexity acquisition.
• Free cash flow (cash flow from operations less capital expenditures) is expected to improve approximately 25%, relative to fiscal 2026.

Azenta does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the Company's control, or cannot be reasonably predicted. These items are uncertain and could have a significant impact on the Company's GAAP results for the guidance periods. Such adjustments include, but are not limited to, transformation costs, restructuring charges, costs related to acquisitions and divestitures, governance-related matters, goodwill and intangible impairments, stock-based compensation, and other gains and charges that are not representative of the normal operations of the business.

Conference Call and Webcast
Azenta management will webcast its fourth quarter and full year fiscal 2026 earnings conference call on November 11, 2026 at 8:30 a.m. Eastern Time. During the call, Company management will respond to questions concerning, but not limited to, the Company's financial performance, business conditions and industry outlook. Management's responses could contain information that has not been previously disclosed.

The call will be broadcast live over the Internet and, together with presentation materials and supplemental information referenced on the call, will be hosted at the Investor Relations section of Azenta's website at https://investors.azenta.com/events. The supplemental information is being posted at the time of this earnings release, and the presentation materials will be posted ahead of the earnings call. A replay of the webcast will be archived on the website for convenient on-demand access.

Regulation G – Use of Non-GAAP Financial Measures
This release includes non-GAAP financial measures, including organic revenue, Adjusted gross profit and margin, Adjusted operating income, expenses and margin, EBITDA, Adjusted EBITDA and Adjusted EBITDA margin, Adjusted net income, Adjusted diluted EPS and free cash flow. Management believes these measures provide investors with additional insight into the results of the Company's business operations, enhance period-to-period comparability and facilitate comparison with peers. Management uses these measures to evaluate business performance and uses organic revenue (referred to as Core Revenue in the Company's proxy statement), Adjusted EBITDA and free cash flow in determining compensation under the Company's annual incentive plan. These non-GAAP financial measures are not presented in accordance with, and are not substitutes for, financial measures prepared in accordance with U.S. generally accepted accounting principles, or GAAP, and should be considered together with the most directly comparable GAAP financial measures. These measures may not be comparable to similarly titled measures used by other companies.

These measures are presented on a continuing operations basis, except free cash flow, which is presented on a total company basis inclusive of B Medical Systems. Adjusted diluted EPS does not exclude stock-based compensation; the Company separately presents Adjusted net income excluding stock-based compensation. Reconciliations to the most directly comparable GAAP measures, and descriptions of the adjustments, are included at the end of this release under "Notes on Non-GAAP Financial Measures." Certain amounts may not sum due to rounding, and all percentages are calculated using unrounded amounts.

"Safe Harbor Statement" under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended
Some statements in this release are forward-looking statements within the meaning of the federal securities laws. These statements are neither promises nor guarantees and involve risks and uncertainties, both known and unknown, that could cause Azenta's actual financial or business results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on the facts and assumptions known to management as of the date they are made.

Forward-looking statements include, but are not limited to, statements regarding the Company's fiscal 2027 guidance and outlook, including revenue, organic revenue growth, Adjusted EBITDA margin expansion and free cash flow expectations; expectations regarding the implementation, integration, commercialization and anticipated benefits of the Company's strategic investments, including the Elegen agreements and SynPlexity acquisition; potential future capital deployment under the Elegen agreements, including future equipment purchases and the potential exercise of the license conversion option; expectations regarding the timing, execution and benefits of operational, commercial and organizational transformation initiatives; anticipated productivity improvements, cost actions and margin expansion; expectations regarding demand trends and end-market conditions; and the Company's long-range financial objectives. Factors that could cause actual results to differ materially from those expressed or implied by forward-looking statements include, but are not limited to: the Company's ability to achieve its fiscal 2027 outlook; the Company's ability to successfully implement, integrate and commercialize its strategic investments, including the Elegen agreements and SynPlexity acquisition, and realize their anticipated benefits; risks associated with future capital deployment and other obligations under the Elegen agreements; the ability to achieve anticipated revenue, margin, cost and productivity improvements; changes in customer demand, purchasing behavior or funding conditions in the markets the Company serves; macroeconomic, geopolitical or regulatory developments; foreign currency fluctuations; supply chain disruptions; competitive dynamics; and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Azenta expressly disclaims any obligation or undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About Azenta Life Sciences
 Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia. For more information, please visit www.azenta.com.

AZENTA INVESTOR CONTACTS:

Yvonne Perron
Vice President, Financial Planning & Analysis and Investor Relations
ir@azenta.com

Maria Isabel Cuartas
Manager Investor Relations
ir@azenta.com

AZENTA, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (In thousands, except per share data)
	Three Months Ended September 30,				Year Ended September 30,
	2026		2025		2026		2025
Revenue
Products	$       45,306		$       48,020		$     165,291		$     173,189
Services	121,782		111,172		456,412		420,632
Total revenue	167,088		159,192		621,703		593,821
Cost of revenue
Products	23,961		26,287		95,850		94,894
Services	66,260		60,631		250,889		228,647
Total cost of revenue	90,221		86,918		346,739		323,541
Gross profit	76,867		72,274		274,964		270,280
Operating expenses
Research and development	10,443		8,258		37,918		30,390
Selling, general and administrative	61,860		61,709		257,526		261,563
Impairment of goodwill and intangible assets	—		—		149,083		—
Restructuring charges	2,058		406		5,136		5,171
Total operating expenses	74,361		70,373		449,663		297,124
Operating income (loss)	2,506		1,901		(174,699)		(26,844)
Other income (expense)
Interest income, net	4,520		5,019		17,830		18,779
Other income (expense), net	526		(620)		5,863		922
Income (loss) from continuing operations before income taxes	7,552		6,300		(151,006)		(7,143)
Income tax expense (benefit)	1,678		(45,353)		6,860		(31,601)
Income (loss) from continuing operations	5,874		51,653		(157,866)		24,458
Income (loss) from discontinued operations, net of tax	915		(776)		(9,119)		(80,221)
Net income (loss)	$        6,789		$      50,877		$   (166,985)		$     (55,763)
Basic net income (loss) per share:
Income (loss) from continuing operations	$          0.14		$          1.13		$         (3.50)		$          0.53
Income (loss) from discontinued operations, net of tax	$          0.02		$         (0.02)		$         (0.20)		$         (1.75)
Net income (loss) per share	$          0.16		$          1.11		$         (3.70)		$         (1.22)
Diluted net income (loss) per share:
Income (loss) from continuing operations	$          0.14		$          1.12		$         (3.50)		$          0.53
Income (loss) from discontinued operations, net of tax	$          0.02		$         (0.02)		$         (0.20)		$         (1.75)
Diluted net income (loss) per share	$          0.16		$          1.11		$         (3.70)		$         (1.22)
Weighted average shares used in computing net income (loss) per share:
Basic	43,264		45,833		45,130		45,743
Diluted	43,465		45,994		45,130		45,896

 

AZENTA, INC. CONSOLIDATED BALANCE SHEETS (unaudited) (In thousands, except share and per share data)
	September 30,
	2026		2025
Assets
Current assets
Cash and cash equivalents	$       193,798		$       279,783
Short-term marketable securities	138,886		61,137
Accounts receivable, net of allowance for expected credit losses ($4,111 and $4,649, respectively)	143,418		142,181
Inventories	77,122		74,956
Short-term restricted cash	265		2,359
Refundable income taxes	10,717		9,728
Contract assets	32,971		37,295
Prepaid expenses and other current assets	26,359		27,365
Current assets held for sale	—		73,535
Total current assets	623,536		708,339
Property, plant and equipment, net	175,245		153,954
Long-term marketable securities	169,200		201,585
Long-term deferred tax assets	499		726
Operating lease right-of-use assets	59,012		54,048
Goodwill	546,259		702,395
Intangible assets, net	79,998		101,814
Long term income taxes receivable	45,600		45,600
Other assets	9,034		6,115
Noncurrent assets held for sale	—		85,006
Total assets	$     1,708,383		$     2,059,582
Liabilities and stockholders' equity
Current liabilities
Accounts payable	$          55,219		$          37,722
Deferred revenue	40,081		31,569
Derivative liability	25,641		33,420
Accrued warranty and retrofit costs	3,544		4,713
Accrued compensation and benefits	33,396		35,799
Customer deposits	33,566		26,499
Accrued income taxes payable	3,517		9,416
Accrued expenses and other current liabilities	38,123		30,268
Current liabilities held for sale	—		28,268
Total current liabilities	233,087		237,674
Long-term deferred tax liabilities	15,338		18,245
Long-term operating lease liabilities	51,874		51,244
Other long-term liabilities	10,863		11,142
Noncurrent liabilities held for sale	—		14,291
Total liabilities	$       311,162		$       332,596
Stockholders' equity
Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding	—		—
Common stock, $0.01 par value - 125,000,000 shares authorized, 55,284,062 shares issued and 41,757,019 shares outstanding at September 30, 2026, 59,320,848 shares issued and 45,858,979 shares outstanding at September 30, 2025	553		594
Additional paid-in capital	424,268		529,605
Accumulated other comprehensive loss	(77,398)		(22,213)
Treasury stock, at cost - 13,527,043 shares at September 30, 2026 and 13,461,869 shares at September 30, 2025	(203,173)		(200,956)
Retained earnings	1,252,971		1,419,956
Total stockholders' equity	1,397,221		1,726,986
Total liabilities and stockholders' equity	$     1,708,383		$     2,059,582

 

AZENTA, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (In thousands)
	Year Ended September 30,
	2026		2025
Cash flows from operating activities
Net loss	$        (166,985)		$          (55,763)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	56,520		61,209
Impairment of goodwill and intangible assets	149,083		—
Non-cash gain from settlement of preexisting contractual relationship	(3,716)		—
Loss on assets held for sale	9,491		93,118
Property, plant and equipment and other asset write-offs	1,363		3,478
Inventory write-downs	4,015		—
Other non-cash adjustments	(1,985)		—
Stock-based compensation	12,243		20,881
Amortization and accretion on marketable securities	(1,424)		(1,578)
Deferred income taxes	(5,170)		(27,038)
Loss on disposals of property, plant and equipment	14		711
Changes in operating assets and liabilities:
Accounts receivable	4,423		21,039
Inventories	(8,041)		(2,671)
Accounts payable	12,662		1,037
Deferred revenue	6,020		641
Accrued warranty and retrofit costs	(424)		(435)
Accrued compensation and tax withholdings	(1,418)		7,427
Long term income taxes receivable	—		(45,600)
Other assets and liabilities	(9,165)		(4,275)
Net cash provided by operating activities	57,506		72,181
Cash flows from investing activities
Purchases of property, plant and equipment	(30,079)		(33,857)
Purchases of marketable securities and other investments	(375,684)		(451,409)
Sales and maturities of marketable securities	328,609		389,452
Acquisition of UK Biocentre, net of cash acquired	(11,150)		—
Proceeds from other investment	—		2,130
Net investment hedge settlement	—		3,223
Proceeds from the sale of B Medical Systems business, net of cash transferred	54,503		—
Net cash used in investing activities	(33,801)		(90,461)
Cash flows from financing activities
Proceeds from issuance of common stock	2,204		2,770
Payments of finance leases	(748)		(985)
Withholding tax payments on net share settlements on equity awards	(2,669)		—
Share repurchases	(118,286)		—
Excise tax payment for settled share repurchases	—		(11,376)
Net cash used in financing activities	(119,499)		(9,591)
Effects of exchange rate changes on cash, cash equivalents and restricted cash	(2,576)		3,566
Net decrease in cash, cash equivalents and restricted cash	(98,370)		(24,305)
Cash, cash equivalents and restricted cash, beginning of period	296,685		320,990
Cash, cash equivalents and restricted cash, end of period	$          198,315		$          296,685
Supplemental disclosures:
Cash paid for income taxes, net	$            18,118		$              6,568
Purchases of property, plant and equipment included in accounts payable and accrued expenses	$              9,404		$              5,546
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
	Year Ended September 30,
	2026		2025
Cash and cash equivalents of continuing operations	$         193,798		$         279,783
Cash included in current assets held for sale	—		13,206
Short-term restricted cash included in prepaid expenses and other current assets	265		2,359
Long-term restricted cash included in other assets	4,252		1,337
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$         198,315		$         296,685

Notes on Non-GAAP Financial Measures - Continuing Operations
Non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusts the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A, costs related to the Company's business transformation initiatives and share repurchases to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers. Management also excludes special charges and gains, such as impairment losses, gains and losses from the sale of assets, certain tax benefits and charges, as well as other gains and charges that are not representative of the normal operations of the business. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not rely on any single measure.

	Quarter Ended
	September 30, 2026				June 30, 2026				September 30, 2025
Amounts in thousands, except per share data	$		per diluted share		$		per diluted share		$		per diluted share
Net income (loss) from continuing operations	$        5,874		$       0.14		$     (1,529)		$      (0.03)		$     51,653		$       1.12
Adjustments:
Amortization of completed technology	2,076		0.05		2,082		0.05		2,088		0.05
Amortization of other intangible assets	3,606		0.08		3,616		0.08		3,977		0.09
Transformation costs(1)	804		0.02		272		0.01		634		0.01
Restructuring charges	2,058		0.05		513		0.01		406		0.01
Merger and acquisition costs(3)	363		0.01		2,248		0.05		87		0.00
Non-recurring other adjustments(4)	142		0.00		—		—		—		—
Purchase accounting adjustments	117		0.00		154		0.00		—		—
Tax adjustments(5)	—		—		—		—		(46,960)		(1.02)
Tax effect of adjustments	(2,753)		(0.06)		(198)		0.00		(2,246)		(0.05)
Adjusted net income from continuing operations	$       12,287		$       0.28		$      7,158		$       0.16		$      9,639		$       0.21
Stock-based compensation, pre-tax	(2,412)		(0.06)		4,692		0.10		3,901		0.08
Tax rate	19 %		—		13 %		—		17 %		—
Stock-based compensation, net of tax	(1,954)		(0.04)		4,082		0.09		3,238		0.07
Adjusted net income excluding stock-based compensation - continuing operations	$       10,333		$       0.24		$     11,240		$       0.25		$     12,877		$       0.28
Shares used in computing adjusted diluted net income per share			43,465				45,286				45,994

	Year Ended
	September 30, 2026				September 30, 2025
Amounts in thousands, except per share data	$		per diluted share		$		per diluted share
Net income (loss) from continuing operations	$    (157,866)		$          (3.50)		$         24,458		$           0.53
Adjustments:
Amortization of completed technology	8,093		0.18		7,965		0.17
Amortization of other intangible assets	14,336		0.32		16,475		0.36
Transformation costs(1)	2,717		0.06		10,405		0.23
Restructuring charges	5,136		0.11		5,171		0.11
Impairment of goodwill and intangible assets(2)	149,083		3.30		—		—
Merger and acquisition costs(3)	4,799		0.11		2,403		0.05
Non-recurring other adjustments(4)	(3,716)		(0.08)		(2,130)		(0.05)
Purchase accounting adjustment	271		0.01		—		—
Tax adjustments(5)	—		—		(39,660)		(0.86)
Tax effect of adjustments	(1,048)		(0.02)		(1,675)		(0.04)
Other adjustments	—		—		38		0.00
Adjusted net income from continuing operations	$       21,805		$           0.48		$       23,450		$           0.51
Stock-based compensation, pre-tax	12,410		0.27		19,849		0.43
Tax rate	19 %		—		17 %		—
Stock-based compensation, net of tax	10,052		0.22		16,475		0.36
Adjusted net income excluding stock-based compensation - continuing operations	$        31,857		$           0.71		$        39,925		$           0.87
Shares used in computing adjusted diluted net income per share			45,130				45,896

(1)	Transformation costs represent expenses associated with discrete strategic initiatives undertaken to simplify, standardize, streamline, and optimize the Company's operations, processes, and systems. These initiatives are intended to generate long-term operational efficiencies and productivity improvements and do not meet the definition of restructuring charges. Transformation costs primarily include asset write-downs associated with technology changes, inventory write-downs related to restructuring activities, and third-party consulting costs incurred to support process and systems redesign efforts.
(2)	Represents a non-cash goodwill impairment charge recognized in the second quarter of fiscal 2026 as a result of the Company's quantitative goodwill impairment analysis as of March 31, 2026, including $112.4 million for the Multiomics reporting unit and $36.6 million for the Sample Management Solutions reporting unit.
(3)	Merger and acquisition costs consist primarily of legal, accounting, valuation, and strategic advisory fees incurred in connection with acquisition and integration activities.
(4)	The Company recognized $3.9 million non-cash gain from the settlement of the pre-existing contractual relationship with UK Biocentre Limited in the second quarter of fiscal 2026. The Company received $2.1 million of cash proceeds from a cost method investment which had no cost basis in the second quarter of fiscal 2025. These are non-recurring and non-operational adjustments.
(5)	The tax adjustments for the fourth quarter of fiscal year 2025 and full year includes a one-time $45.6 million benefit related to a worthless stock deduction on one of the Company's foreign subsidiaries that is excluded from non-GAAP results. The full year adjustments also includes a one-time tax expense of $6.4 million driven by a repatriation of historical earnings from China.

 

	Quarter Ended						Year Ended
Dollars in thousands	September 30, 2026		June 30, 2026		September 30, 2025		September 30, 2026		September 30, 2025
GAAP net income (loss)	$      6,789		$      2,456		$     50,877		$   (166,985)		$    (55,763)
Less: Income (loss) from discontinued operations	915		3,985		(776)		(9,119)		(80,221)
GAAP net income (loss) from continuing operations	5,874		(1,529)		51,653		(157,866)		24,458
Adjustments:
Interest income, net	(4,520)		(3,825)		(5,019)		(17,830)		(18,779)
Income tax expense (benefit)	1,678		2,375		(45,353)		6,860		(31,601)
Depreciation	9,579		7,861		8,338		33,986		32,033
Amortization of completed technology	2,076		2,082		2,088		8,093		7,965
Amortization of other intangible assets	3,606		3,616		3,977		14,336		16,475
Earnings before interest, taxes, depreciation and amortization - Continuing operations	$     18,293		$     10,580		$     15,684		$   (112,421)		$     30,551
	Quarter Ended						Year Ended
Dollars in thousands	September 30, 2026		June 30, 2026		September 30, 2025		September 30, 2026		September 30, 2025
Earnings before interest, taxes, depreciation and amortization - Continuing operations	$     18,293		$     10,580		$     15,684		$   (112,421)		$     30,551
Adjustments:
Stock-based compensation	(2,412)		4,692		3,901		12,410		19,849
Restructuring charges	2,058		513		406		5,136		5,171
Impairment of goodwill and intangible assets(1)	—		—		—		149,083		—
Merger and acquisition costs(2)	363		2,248		87		4,799		2,403
Transformation costs(3)	804		272		634		2,717		10,405
Non-recurring other adjustments(4)	142		—		—		(3,716)		(2,130)
Purchase accounting adjustment	117		154		—		271		—
Other adjustments	—		—		—		16		34
Adjusted earnings before interest, taxes, depreciation and amortization - Continuing operations	$     19,365		$     18,459		$     20,712		$     58,295		$     66,283

(1)	Represents a non-cash goodwill impairment charge recognized in the second quarter of fiscal 2026 as a result of the Company's quantitative goodwill impairment analysis as of March 31, 2026, including $112.4 million for the Multiomics reporting unit and $36.6 million for the Sample Management Solutions reporting unit.
(2)	Merger and acquisition costs consist primarily of legal, accounting, valuation, and strategic advisory fees incurred in connection with acquisition and integration activities.
(3)	Transformation costs represent expenses associated with discrete strategic initiatives undertaken to simplify, standardize, streamline, and optimize the Company's operations, processes, and systems. These initiatives are intended to generate long-term operational efficiencies and productivity improvements and do not meet the definition of restructuring charges. Transformation costs primarily include asset write-downs associated with technology changes, inventory write-downs related to restructuring activities, and third-party consulting costs incurred to support process and systems redesign efforts.
(4)	The Company recognized $3.9 million non-cash gain from the settlement of the pre-existing contractual relationship with UK Biocentre Limited in the second quarter of fiscal 2026. The Company received $2.1 million of cash proceeds from a cost method investment which had no cost basis in the second quarter of fiscal 2025. These are non-recurring and non-operational adjustments.

 

	Quarter Ended
Dollars in thousands	September 30, 2026				June 30, 2026				September 30, 2025
GAAP gross profit	$    76,867		46.0 %		$    72,356		44.9 %		$    72,274		45.4 %
Adjustments:
Amortization of completed technology	2,076		1.2 %		2,082		1.3 %		2,088		1.3 %
Adjusted gross profit	$    78,943		47.2 %		$    74,438		46.2 %		$    74,362		46.7 %

	Year Ended
Dollars in thousands	September 30, 2026					September 30, 2025
GAAP gross profit	$          274,964		44.2 %			$          270,280		45.5 %
Adjustments:
Amortization of completed technology	8,093		1.3 %			7,965		1.3 %
Transformation costs(1)	—		— %			52		0.0 %
Other Adjustments	—		— %			18		0.0 %
Adjusted gross profit	$          283,057		45.5 %			$          278,315		46.9 %

(1)

Transformation costs represent expenses associated with discrete strategic initiatives undertaken to simplify, standardize, streamline, and optimize the Company's operations, processes, and systems. These initiatives are intended to generate long-term operational efficiencies and productivity improvements and do not meet the definition of restructuring charges. Transformation costs primarily include asset write-downs associated with technology changes, inventory write-downs related to restructuring activities, and third-party consulting costs incurred to support process and systems redesign efforts.

 

	Sample Management Solutions												Multiomics
	Quarter Ended												Quarter Ended
Dollars in thousands	September 30, 2026				June 30, 2026				September 30, 2025				September 30, 2026				June 30, 2026				September 30, 2025
GAAP gross profit	$       44,408		47.4 %		$       39,126		44.3 %		$       41,175		47.9 %		$       32,459		44.2 %		$       33,230		45.6 %		$       31,094		42.5 %
Adjustments:
Amortization of completed technology	1,386		1.5 %		1,393		1.6 %		1,226		1.4 %		690		0.9 %		689		0.9 %		862		1.2 %
Adjusted gross profit	$       45,794		48.9 %		$       40,519		45.9 %		$       42,401		49.3 %		$       33,149		45.1 %		$       33,919		46.5 %		$       31,956		43.7 %

	Segment Total
	Quarter Ended
Dollars in thousands	September 30, 2026				June 30, 2026				September 30, 2025
GAAP gross profit	$        76,867		46.0 %		$        72,356		44.9 %		$        72,274		45.4 %
Adjustments:
Amortization of completed technology	2,076		1.2 %		2,082		1.3 %		2,088		1.3 %
Adjusted gross profit	$        78,943		47.2 %		$        74,438		46.2 %		$        74,362		46.7 %

	Sample Management Solutions									Multiomics
	Year Ended									Year Ended
Dollars in thousands	September 30, 2026					September 30, 2025				September 30, 2026					September 30, 2025
GAAP gross profit	$  156,401		45.4 %			$  156,645		48.3 %		$  118,563		42.8 %			$  113,635		42.2 %
Adjustments:
Amortization of completed technology	5,344		1.6 %			4,522		1.4 %		2,749		1.0 %			3,443		1.3 %
Transformation costs(1)	—		— %			52		0.0 %		—		— %			—		— %
Other Adjustments	—		— %			26		0.0 %		—		— %			(8)		0.0 %
Adjusted gross profit	$  161,745		47.0 %			$  161,245		49.7 %		$  121,312		43.8 %			$  117,070		43.5 %

	Segment Total
	Year Ended
Dollars in thousands	September 30, 2026					September 30, 2025
GAAP gross profit	$          274,964		44.2 %			$          270,280		45.5 %
Adjustments:
Amortization of completed technology	8,093		1.3 %			7,965		1.3 %
Transformation costs(1)	—		— %			52		0.0 %
Other Adjustments	—		— %			18		0.0 %
Adjusted gross profit	$          283,057		45.5 %			$          278,315		46.9 %

(1)

Transformation costs represent expenses associated with discrete strategic initiatives undertaken to simplify, standardize, streamline, and optimize the Company's operations, processes, and systems. These initiatives are intended to generate long-term operational efficiencies and productivity improvements and do not meet the definition of restructuring charges. Transformation costs primarily include asset write-downs associated with technology changes, inventory write-downs related to restructuring activities, and third-party consulting costs incurred to support process and systems redesign efforts.

 

	Total Segments						Corporate						Total
	Quarter Ended						Quarter Ended						Quarter Ended
Dollars in thousands	September 30, 2026		June 30, 2026		September 30, 2025		September 30, 2026		June 30, 2026		September 30, 2025		September 30, 2026		June 30, 2026		September 30, 2025
GAAP operating income (loss)	$    9,063		$    2,051		$    6,986		$   (6,557)		$   (6,229)		$   (5,085)		$    2,506		$   (4,178)		$    1,901
Adjustments:
Amortization of completed technology	2,076		2,082		2,088		—		—		—		2,076		2,082		2,088
Amortization of other intangible assets	—		49		—		3,606		3,567		3,977		3,606		3,616		3,977
Transformation costs(1)	179		56		(57)		625		216		691		804		272		634
Restructuring charges	—		—		—		2,058		513		406		2,058		513		406
Merger and acquisition costs(3)	60		204		—		303		2,044		87		363		2,248		87
Purchase accounting and other adjustments	154		154		73		(38)		—		(73)		116		154		—
Adjusted operating income (loss)	$   11,532		$    4,596		$    9,090		$       (3)		$      111		$        3		$   11,529		$    4,707		$    9,093

	Total Segments				Corporate				Total
	Year Ended				Year Ended				Year Ended
Dollars in thousands	September 30, 2026		September 30, 2025		September 30, 2026		September 30, 2025		September 30, 2026		September 30, 2025
GAAP operating income (loss)	$        705		$      4,710		$   (175,404)		$    (31,554)		$   (174,699)		$    (26,844)
Adjustments:
Amortization of completed technology	8,093		7,965		—		—		8,093		7,965
Amortization of other intangible assets	86		—		14,250		16,475		14,336		16,475
Transformation costs(1)	348		2,820		2,369		7,585		2,717		10,405
Restructuring charges	—		—		5,136		5,171		5,136		5,171
Impairment of goodwill and intangible assets(2)	—		—		149,083		—		149,083		—
Merger and acquisition costs(3)	264		—		4,535		2,403		4,799		2,403
Purchase accounting and other adjustments	294		118		—		(84)		294		34
Adjusted operating income (loss)	$      9,790		$     15,613		$        (31)		$         (4)		$      9,759		$     15,609

(1)	Transformation costs represent expenses associated with discrete strategic initiatives undertaken to simplify, standardize, streamline, and optimize the Company's operations, processes, and systems. These initiatives are intended to generate long-term operational efficiencies and productivity improvements and do not meet the definition of restructuring charges. Transformation costs primarily include asset write-downs associated with technology changes, inventory write-downs related to restructuring activities, and third-party consulting costs incurred to support process and systems redesign efforts.
(2)	Represents non-cash goodwill impairment charges recognized in the second quarter of fiscal 2026 as a result of the Company's quantitative goodwill impairment analysis as of March 31, 2026, including $112.4 million for the Multiomics reporting unit and $36.6 million for the Sample Management Solutions reporting unit.
(3)	Merger and acquisition costs consist primarily of legal, accounting, valuation, and strategic advisory fees incurred in connection with acquisition and integration activities.

 

	Sample Management Solutions						Multiomics						Azenta Total
	Quarter Ended						Quarter Ended						Quarter Ended
Dollars in millions	September 30, 2026		September 30, 2025		Change		September 30, 2026		September 30, 2025		Change		September 30, 2026		September 30, 2025		Change
Revenue	$       94		$       86		9 %		$       73		$       73		0 %		$      167		$      159		5 %
Acquisitions	(4)		—		(5) %		—		—		— %		(4)		—		(3) %
Currency exchange rates	0		—		0 %		(1)		—		(1) %		(0)		—		0 %
Organic revenue	$       90		$       86		4 %		$       73		$       73		(1) %		$      162		$      159		2 %
	Sample Management Solutions						Multiomics						Azenta Total
	Year Ended						Year Ended						Year Ended
Dollars in millions	September 30, 2026		September 30, 2025		Change		September 30, 2026		September 30, 2025		Change		September 30, 2026		September 30, 2025		Change
Revenue	$      344		$      325		6 %		$      277		$      269		3 %		$      622		$      594		5 %
Acquisitions	(10)		—		(3) %		—		—		— %		(10)		—		(2) %
Currency exchange rates	(4)		—		(1) %		(5)		—		(2) %		(8)		—		(1) %
Organic revenue	$      331		$      325		2 %		$      273		$      269		1 %		$      604		$      594		2 %

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-reports-fourth-quarter-and-full-year-results-for-fiscal-2026-ended-september-30-2026-302935511.html

SOURCE Azenta

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Azenta's fiscal 2026 revenue and earnings results?

Azenta reported $622 million in revenue, up 5% year over year, and a continuing-operations diluted loss per share of ($3.50), versus earnings of $0.53 in fiscal 2025. Organic revenue grew 2%. Total diluted loss per share, including discontinued operations, was ($3.70), compared with ($1.22).

What is Azenta's fiscal 2027 outlook?

Azenta expects revenue of approximately $648–$660 million and organic revenue growth of approximately 3%–5%. It expects adjusted EBITDA margin expansion of 200–250 basis points, inclusive of expected dilution of 100 basis points from Elegen and SynPlexity, and approximately 25% improvement in free cash flow relative to fiscal 2026.

How can Azenta convert its Elegen license into a perpetual license?

Azenta can exercise an option between 12 and 18 months after execution to convert the license into an irrevocable, perpetual, exclusive, royalty-free license. The conversion costs $25.0 million plus any unpaid license fees and remains subject to the license's terms.

How much remains under Azenta's share repurchase authorization?

Azenta had $131.8 million available for future repurchases as of September 30, 2026. The program authorizes up to $250 million of common-stock repurchases through December 31, 2028.